药物涂层球囊治疗冠状动脉原位病变的有效性及安全性

目的 观察药物涂层球囊介入治疗对冠状动脉原位病变患者术后MACE事件发生的影响。方法 选择于2021年2月至2022年6月就诊且需进行介入治疗的冠状动脉原位病变的85例患者，用随机数字表法分为观察组和对照组。其中40例观察组患者接受药物涂层球囊介入治疗，45例对照组患者接受药物洗脱支架介入治疗。分别在术前及术后不同时间检测管腔直径。比较两组手术即刻成功率、术中并发症发生情况；比较两组患者术前、术后即刻、术后6个月最小管腔直径（MLD）和管腔狭窄程度；评估两组术后6个月时晚期管腔丢失（LLL）；观察两组术后6个月内不良心血管事件（MACE）和靶血管病变处再狭窄情况。结果 观察组即刻手术成功率为95.00%，对照组即刻手术成功率为97.78%，两组即刻手术成功率差异无统计学意义（P>0.05）；两组患者术中并发症发生差异无统计学意义（P>0.05）；观察组MLD术后即刻与术后6个月均低于对照组（P<0.05）；观察组管腔狭窄程度术后即刻均高于对照组（P<0.05），而术后6个月与对照组比较差异无统计学意义（P>0.05）；观察组管腔再狭窄小于对照组，累计MACE发生率低于对照组（P<0.05）。结论 药物涂层球囊介入治疗即刻成功率较高，明显改善动脉血管狭窄情况，安全性较好。

Efficacy and safety of drug-coated balloon in the treatment of de novo coronary artery disease

Objective To explore the safety and efficacy of drug-coated balloon (DCB) in the treatment of de novo coronary artery disease. Methods A total of 85 patients with de novo coronary artery disease undergoing interventional therapy in Anqing First People''s Hospital Affiliated to Anhui Medical University from February 2021 to June 2022 were retrospectively included, and were divided into drug-eluting stent (DES) group (n=45) and DCB group (n=40) according to different interventional therapies. The minimal lumen diameter (MLD) and the degree of lumen stenosis before surgery, immediately after surgery and at 6 months after surgery, immediate success rate of surgery and incidence of intraoperative complications, late lumen loss (LLL) at 6 months after surgery, incidence of major adverse cardiovascular event (MACE) within 6 months after surgery were compared between the two groups. Results Immediately and at 6 months after surgery, MLD in DCB group was significantly shorter than that in DES group (P<0.001). Immediately after surgery, lumen stenosis in DCB group was significantly severer than that in DES group (P<0.001), but there was no significant difference between the two groups at 6 months after surgery. There was no significant difference in immediate success rate of surgery between DCB group and DES group (95.00% vs 97.78%). There was no significant difference in incidence of intraoperative complications between the two groups. At 6 months after surgery, incidences of LLL and MACE in DCB group were significantly lower than those in DES group (P<0.05). Conclusions DCB interventional therapy has high immediate success rate of surgery for de novo coronary artery disease, which can significantly improve arterial vascular stenosis, with good safety.